Caris Life Sciences/$CAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Caris Life Sciences
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Ticker
$CAI
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,769
ISIN
US1421521071
Website
CAI Metrics
BasicAdvanced
$7.4B
-
-$10.43
-
-
Price and volume
Market cap
$7.4B
52-week high
$30.70
52-week low
$25.56
Financial strength
Current ratio
1.053
Quick ratio
0.699
Long term debt to equity
-99.988
Total debt to equity
-118.678
Interest coverage (TTM)
-4.16%
Profitability
EBITDA (TTM)
-184.595
Gross margin (TTM)
46.71%
Net profit margin (TTM)
-60.43%
Operating margin (TTM)
-49.25%
Revenue per employee (TTM)
$260,000
Management effectiveness
Valuation
Price to revenue (TTM)
2.101
Price to book
-0.36
Price to tangible book (TTM)
-0.36
Price to free cash flow (TTM)
-4.484
Free cash flow yield (TTM)
-22.30%
Free cash flow per share (TTM)
-595.96%
Growth
Bulls say / Bears say
Caris Life Sciences' strong Nasdaq debut, with shares rising nearly 29% to open at $27, valued the company at approximately $7.66 billion, indicating robust investor confidence. (reuters.com)
The multi-year strategic partnership with Moderna aims to advance mRNA-based oncology therapeutics, leveraging Caris' extensive molecular data to enhance Moderna's oncology pipeline. (markets.businessinsider.com)
Caris reported a significant revenue increase to $412.3 million in 2024 from $306.1 million in 2023, reflecting strong financial growth ahead of its IPO. (tradingview.com)
Despite the successful IPO, Caris has experienced negative cash flow since its inception, posting net losses of $257.1 million for 2024 and $102.6 million for the first quarter of 2025, which may raise concerns about profitability. (fiercebiotech.com)
The healthcare sector, including biotech, has lagged in IPO activity, contributing only 5% of new listings in 2025 compared to 70% from finance and tech, potentially indicating less investor interest in this sector. (reuters.com)
Caris' reliance on partnerships, such as those with Moderna and Incyte, means its success is partially dependent on external collaborations, which can introduce risks if these partnerships face challenges. (markets.businessinsider.com, stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 20 Jun 2025.
CAI Financial Performance
Revenues and expenses
CAI News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Caris Life Sciences stock?
Caris Life Sciences (CAI) has a market cap of $7.4B as of July 01, 2025.
What is the P/E ratio for Caris Life Sciences stock?
The price to earnings (P/E) ratio for Caris Life Sciences (CAI) stock is 0 as of July 01, 2025.
Does Caris Life Sciences stock pay dividends?
No, Caris Life Sciences (CAI) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Caris Life Sciences dividend payment date?
Caris Life Sciences (CAI) stock does not pay dividends to its shareholders.
What is the beta indicator for Caris Life Sciences?
Caris Life Sciences (CAI) does not currently have a Beta indicator.